Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VYACH
ADC Name
CBX-12
Synonyms
CBX 12; CBX12
   Click to Show/Hide
Organization
Cybrexa, Inc.
Drug Status
Phase 1/2
Indication
In total 2 Indication(s)
Epithelial ovarian cancer [ICD11:2B5D]
Phase 2
Small cell lung cancer [ICD11:2C25]
Phase 2
Antibody Name
Undisclosed
Antigen Name
Undisclosed
Payload Name
Exatecan
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Undisclosed
Combination Type
Alphale-exatecan
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 9.96
%
HCT 116 cells
Colon cancer
Tumor Growth Inhibition value (TGI) 
≈ 42.76
%
MDA-MB-231 cells
Breast adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 56.7
%
Colon cancer cells
Colon cancer
Tumor Growth Inhibition value (TGI) 
≈ 76.32
%
MDA-MB-231 cells
Breast adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 81.22
%
Colon cancer cells
Colon cancer
Tumor Growth Inhibition value (TGI) 
≈ 95.4
%
MDA-MB-231 cells
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 9.96% (Day 23)
Method Description
Ceralasertib=25 mg/kg.
In Vivo Model Colon cancer CDX model
In Vitro Model Colon cancer HCT 116 cells CVCL_0291
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 42.76% (Day 35)
Method Description
Ceralasertib=25 mg/kg.
In Vivo Model Breast cancer CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 56.70% (Day 23)
Method Description
CBX-12=5 mg/kg.
In Vivo Model Colon cancer CDX model
In Vitro Model Colon cancer Colon cancer cells Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 76.32% (Day 35)
Method Description
CBX-12=10 mg/kg.
In Vivo Model Breast cancer CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 81.22% (Day 23)
Method Description
Ceralasertib=25 mg/kg + CBX-12=5 mg/kg.
In Vivo Model Colon cancer CDX model
In Vitro Model Colon cancer Colon cancer cells Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 95.40% (Day 35)
Method Description
Ceralasertib=25 mg/kg + CBX-12=10 mg/kg.
In Vivo Model Breast cancer CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.